Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Abstract In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | https://doi.org/10.1186/s12967-022-03744-6 |
| _version_ | 1811198502310510592 |
|---|---|
| author | Tomer Meirson Valerio Nardone Francesca Pentimalli Gal Markel David Bomze Maria D’Apolito Pierpaolo Correale Antonio Giordano Luigi Pirtoli Camillo Porta Steven G Gray Luciano Mutti |
| author_facet | Tomer Meirson Valerio Nardone Francesca Pentimalli Gal Markel David Bomze Maria D’Apolito Pierpaolo Correale Antonio Giordano Luigi Pirtoli Camillo Porta Steven G Gray Luciano Mutti |
| author_sort | Tomer Meirson |
| collection | DOAJ |
| description | Abstract In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we summarize the most relevant pertinent and available literature on this topic, and use an analysis of the reliability of the trials submitted for registration and/or recently published as a case in point to raise concerns with respect to appropriate trial design, biomarker based stratification and to highlight the ongoing need for balancing the benefit/cost ratio for both patients and healthcare providers. |
| first_indexed | 2024-04-12T01:31:35Z |
| format | Article |
| id | doaj.art-31b55a1ccc204e26bbba66e8945e4d5e |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-04-12T01:31:35Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-31b55a1ccc204e26bbba66e8945e4d5e2022-12-22T03:53:27ZengBMCJournal of Translational Medicine1479-58762022-12-012011910.1186/s12967-022-03744-6Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson0Valerio Nardone1Francesca Pentimalli2Gal Markel3David Bomze4Maria D’Apolito5Pierpaolo Correale6Antonio Giordano7Luigi Pirtoli8Camillo Porta9Steven G Gray10Luciano Mutti11Davidoff Cancer Center, Rabin Medical Center-Beilinson HospitalDepartment of Precision Oncology, University Hospital of Campania L. VanvitelliDipartimento di Medicina e Chirurgia, Libera Università Mediterranea “Giuseppe Degennaro”Davidoff Cancer Center, Rabin Medical Center-Beilinson HospitalSackler Faculty of Medicine, Tel Aviv UniversityUnit of Medical Oncology, Oncology Department, Grand Metropolitan Hospital Bianchi Melacrino MorelliUnit of Medical Oncology, Oncology Department, Grand Metropolitan Hospital Bianchi Melacrino MorelliSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple UniversitySbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple UniversityInterdisciplinary Department of Medicine, University of Bari “Aldo Moro” and A.O.U. Consorziale Policlinico di BariThoracic Oncology Research Group, Trinity St James’s Cancer Institute, St James’s HospitalSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple UniversityAbstract In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we summarize the most relevant pertinent and available literature on this topic, and use an analysis of the reliability of the trials submitted for registration and/or recently published as a case in point to raise concerns with respect to appropriate trial design, biomarker based stratification and to highlight the ongoing need for balancing the benefit/cost ratio for both patients and healthcare providers.https://doi.org/10.1186/s12967-022-03744-6 |
| spellingShingle | Tomer Meirson Valerio Nardone Francesca Pentimalli Gal Markel David Bomze Maria D’Apolito Pierpaolo Correale Antonio Giordano Luigi Pirtoli Camillo Porta Steven G Gray Luciano Mutti Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology Journal of Translational Medicine |
| title | Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| title_full | Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| title_fullStr | Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| title_full_unstemmed | Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| title_short | Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| title_sort | analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology |
| url | https://doi.org/10.1186/s12967-022-03744-6 |
| work_keys_str_mv | AT tomermeirson analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT valerionardone analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT francescapentimalli analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT galmarkel analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT davidbomze analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT mariadapolito analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT pierpaolocorreale analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT antoniogiordano analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT luigipirtoli analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT camilloporta analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT stevenggray analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology AT lucianomutti analysisofnewtreatmentsproposedformalignantpleuralmesotheliomaraisesconcernsabouttheconductionofclinicaltrialsinoncology |